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Bryan M. Grogan,1 Laura Tabellini,1 Barry Storer,1,2 Tara E. Bumgarner,1
Claudia C. Astigarraga,1 Mary E. D. Flowers,1,2 Stephanie J. Lee,1,2
Paul J. Martin,1,2 Edus H. Warren,1,2 John A. Hansen1,21We tested the hypothesis that changes in the phenotype of CD8 T cells from patients with chronic graft-
versus-host disease (cGVHD) correlate with disease activity, and resolve or normalize in clinically tolerant
patients successfully withdrawn from immunosuppression therapy (IST). No significant difference was found
in the absoluteCD81T cell counts among cGVHDpatients, tolerant patients, and healthy controls. However,
comparedwith healthy normal controls, CD81T cells from cGVHDpatients had decreased expression of the
IL-7 receptor and an increase in effector T cells, Ki-67, and perforin expression and apoptosis, suggesting that
activation, differentiation, and proliferation of host-reactive CD81 effector T cells is a mechanism by which
cGVHD is sustained and persists. The increase in effector T cells was most prominent in older patients
and patients who were cytomegalovirus seropositive before transplantation. Use of IST was associated
with a decreased number of CD45RA2 CD81 effector T cells, a decreased expression of Ki-67, and an in-
creased expression of CD95 (Fas). Together, these results demonstrate that CD81 T cells in patients with
cGVHD are characterized by an increased level of activation and proliferation, and an expansion of effector
cells that appear to be selectively sensitive to IST compared with other CD81 T cells. In GVHD-free tolerant
patients, CD81 T cells showed an increased expression of granzyme and HLA-DRmolecules compared with
CD81 T cells from healthy controls, indicating that clinical tolerance in these patients can occur without full
normalization of the CD81 T cell phenotype.
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Chronicgraft-versus-hostdisease (cGVHD)isa fre-
quent complication of allogeneic hematopoietic cell
transplantation (HCT), affecting 40% to 60% of pa-
tients with onset occurring within 6 to 24 months
post-HCT [1]. Chronic GVHD is more likely to occur
in patients who have previously had acute GVHD
(aGVHD), but not all patients with resolved aGVHD
develop cGVHD. Chronic GVHD can also develop
in the absence of prior aGVHD [2-4]. Duration of
cGVHD is variable and on average requires systemic
immunosuppression therapy (IST) for a median of 24
to36months [5].Absenceof aGVHDorcGVHDactiv-1Fred Hutchinson Cancer Research Center, Seattle,
ington; and 2UniversityofWashington,Seattle,Washington.
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6/j.bbmt.2011.03.007ity after withdrawal of IST has been interpreted as indi-
cating the development of clinical immunologic
tolerance [1,2,5,6]. It is unknown, however, whether
‘‘clinical tolerance’’ following HCT meets the classical
experimental definition of immunologic tolerance.
The mechanism by which cGVHD evolves into
quiescence characterized by lack of clinical signs and
symptoms without need for immune suppressive
medications is also unknown.
Donor T cells are recognized as the primary medi-
ators of aGVHD, but less is known about the role of
T cells in cGVHD. It is commonly assumed that
cGVHD is mediated and sustained by donor T cells
reactive to host-specific alloantigen, although immune
dysfunction and autoreactivity may also contribute to
the pathologic lesions characteristic of cGVHD
[7,8]. Two previous studies have examined CD81
T cells in patients with cGVHD. Yamashita et al. [9]
reported a significant increase in CD45RA2CCR71
central memory T cells, andD’Asaro et al. [10] showed
an increase in CD45RA1CCR72 effector T cells in
patients with cGVHD. In the study reported here,
we performed a cross-sectional study of patients re-
turning at various times posttransplantation for1121
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blood samples were obtained and examined for the rel-
ative numbers of na€ıve (TN), central memory (TCM),
effector memory (TEM), and effector (TEFF) CD8
1
T cell subsets as well as T cell effector molecules and
activation markers to test the hypotheses (1) that
changes in CD81 T cell phenotype in cGVHD pa-
tients correlates with disease activity, (2) that these
changes resolve or normalize in clinically tolerant pa-
tients who have been successfully withdrawn from
IST without recurrence of GVHD, and (3) that IST
use is associated with specific CD8 phenotypes in pa-
tients with cGVHD.Our major findings include an in-
crease in CD81 TEFF cells overall, an increased
expression of perforin and Ki-67, and a decrease in
TN cells in patients with cGVHD, along with a de-
crease in CD45RA2 TEFF cells during IST. TEFF
levels, and perforin and Ki-67 expression were normal
in tolerant patients; however, tolerant patients also
showed an unexpected increase in the expression of
HLA-DR and granzyme A. These results overall pro-
vide a framework for future functional studies aimed at
defining the mechanism(s) by which clinical tolerance
occurs following HCT.METHODS
Study Population and Samples
The study population included 273 patients who
had a comprehensive history and physical examination
for the presence or absence of cGVHD at our Long-
Term Follow-Up Clinic. All patients received T cell
replete bone marrow (n 5 53), mobilized peripheral
blood cells (n 5 218), or umbilical cord bloodGVH
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nancy or myelodysplasia. Cyclosporine or tacrolimus,
and short methotrexate or mycophenolate mofetil,
were given for aGVHD prophylaxis. Heparinized
blood was obtained from patients at a median of 28
months post-HCT (range: 6-271 months), and from
healthy normal volunteers who had no history of
HCT (‘‘controls’’). The median age of the patients at
the time of transplantation was 46 years (range: 12-
73), and the median age of their donors was 38 years
(range: 0-76). The median age of healthy normal con-
trols was 37 years (range: 22-73). Peripheral blood
mononuclear cells were isolated by Ficoll-Hypaque
density centrifugation, washed, and aliquoted for cryo-
preservation in 10% DMSO and 90% fetal bovine se-
rum, and were later thawed for cell surface and
intracellular staining. All participants gave informed
consent according to institutional review board ap-
proved protocols.Classification of cGVHD
Graft-versus-host disease (GVHD) status was
evaluated at the time that blood samples were ob-
tained. A diagnosis of clinical cGVHDwas established
according to the recommendations of the National
Institutes of Health Consensus Conference [11,12].
Clinical tolerance was defined as the absence of all
reversible signs and symptoms of GVHD in patients
withdrawn from all IST for at least 3 months at the
time of blood collection and with 6 months of
additional follow-up without recurrence of cGVHD.
Patients were classified for evidence of disease activity
and use of IST and assigned to 1 of 4 categories asD Activity 1
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quiescent cGVHD who were still on IST were ex-
cluded from the study. The remaining patients were
classified into 3 groups as follows: (1) cGVHD, receiv-
ing IST; (2) cGVHDwithout IST; and (3) tolerant, ei-
ther with no history of cGVHD or after recovery from
cGVHD.
Cell Surface and Annexin Staining
Thawed peripheral blood mononuclear cells were
examined by flow cytometry after staining with a series
of fluorochrome-labeled antihuman monoclonal anti-
bodies for cell-surface molecules. Cells subjected to
3-color staining were analyzed on a BD FACScan and
cells stained for .3 colors were analyzed on a BD
LSRII. The collected data were further analyzed with
the use of BD CellQuest Pro software. Reagents in-
cluded CD8 FITC, CD95 (FAS) FITC, CD127 (IL-
7Ra) PE, CD8 PE-Cy5, HLA-DR PerCP-Cy5.5,
CD279 (PD-1) APC, and CD3 APC-Cy7 (BD Phar-
mingen, San Diego, CA), CD62L PerCP-Cy5.5,
CD45RA Pacific Blue, and CD62L Alexa Fluor 700
(Biolegend, SanDeigo, CA). Isotype-matched negative
control antibodies included IgG1k FITC, IgG1k PE,
IgG2ak PerCP-Cy5.5, IgG1k APC, IgG1k APC-
Cy7, and IgG1k Alexa Fluor 700 isotype antibodies
(BD Pharmingen), and with IgG1k PerCP-Cy5.5,
IgG1k PE-Cy7, IgG2bk APC, and IgG2bk Pacific
Blue (Biolegend). Apoptosis was assessed by staining
thawed cells with Annexin V FITC (Apoptosis Detec-
tion Kit I, BD Pharmingen) at 24 hours after in vitro
culture in RPMI 1640 (Gibco, Gaithersburg, MD)
with 10% fetal bovine serum (Invitrogen, Carlsbad,
CA) in a CO2 incubator at 37
C.
Intracellular Staining
Staining of CD81 T cell subsets for cytoplasmic
proteins was accomplished in a 2-step process. First,
cell-surface staining was performed, then cells were
fixed and permeabilized for intracellular staining
with the BD Pharmingen Cytofix/Cytoperm fixation/
permeabilization reagents and protocol according to
the manufacturer’s instructions, and stained with the
following antibodies: FITC-conjugated Ki-67 (BD
Pharmingen); PerCP-Cy5.5-conjugated Granzyme A
and APC-conjugated Perforin (Biolegend).
Definition of CD81 T Cells
Two populations of CD81T cells can be identified
according to the expression level of CD8 as CD8bright
and CD8dim. Approximately 80% of the CD81 popu-
lation stained CD8bright in both patients and normal
controls (data not shown). The composition of the
CD8dim and CD8bright subsets were examined in detail
in 46 patients and 9 controls by staining for CD3,
CD56, and CD4. The majority of the CD8dim cellsin both patients and controls were CD561 (62.0% 6
2.5% and 64.8% 6 3.3%, P 5 .50), and\25% were
CD31CD42CD562 (22.5% 6 1.7% and 23.8% 6
4.2%, respectively), indicating that the CD8dim popu-
lation consisted mostly of natural killer or natural
killer T cells. In contrast, 87.4% 6 1.1% of patient
and 88.3% 6 2.2% of control CD8bright cells were
CD31CD42CD562. Based on these findings, we re-
stricted our study to the CD8bright lymphocyte popula-
tion, thus excluding from the subsequent analysis
natural killer and natural killer T cells [13,14].
Definition of CD81 T Cell Subsets
CD8 subsets were characterized according to ex-
pression of CD62L and CD127 as previously de-
scribed by Bachmann et al. [19] and Huster et al.
[20]. Staining with CD45RA was included to help dis-
tinguish na€ıve and central memory CD81 T cells, and
to serve as a marker for identifying the CD45RA2 and
CD45RA1 CD81 TEFF subsets. CD8
1 T cells were
gated to define subsets in the following fashion: na€ıve
(TN), CD62L
1CD1271CD45RA1; central memory
(TCM), CD62L
1CD1271CD45RA2; and effector
memory (TEM), CD62L
2CD1271CD45RA2. CD81
effector (TEFF) T cells were defined as CD62L
2
CD1272. CD45RA expression was used to further
subdivide TEFF into RA
1 and RA2 subsets (illustrated
in Figure 2).
Statistical Analysis
Multivariate regression analysis was used to com-
pare T cell counts among patients who had cGVHD
without IST, cGVHD during IST, tolerant patients,
and healthy normal controls, adjusting for age of pa-
tients and controls. Clinical variables that might affect
the observed T cell counts and phenotype including
hematopoietic cell source (marrow, peripheral blood),
donor relationship (related, unrelated), age of patient
at the time of HCT and at the time of study, cytomeg-
alovirus (CMV) serostatus of the patient before HCT,
sex mismatch (female donor for a male recipient,
other), cGVHD status at the time of study (presence,
absence), use of IST (yes, no), history of aGVHD
(yes, no), history of cGVHD (yes, no), and time from
transplantation were examined in a multivariate re-
gression model (results of the multivariate analysis
are summarized in Supplemental Tables S1-S3).
P values were calculated using a 2-tailed t test and
were adjusted for age at the time of sample collection
when comparing patients and normal controls. Donor
age was also examined but had no significant effect on
the numbers or phenotypes of T cells after HCT (data
not shown). Pearson correlation coefficients were cal-
culated to evaluate the relationship between age and
T cell counts in patients and controls. All P values
are 2 sided and are not adjusted for multiple
Figure 2. Staining of CD8 subsets. Thawed peripheral blood mononu-
clear cells were stained with CD82FITC, CD45RA2Pacific Blue,
CD127-PE, and CD62L-PerCP-Cy5.5 antibodies and PBL were gated us-
ing CellQuest Pro. (A) Subsequent gating was performed on
CD8brightCD45RA2 (gate R2) and CD8brightCD45RA1 (gate R3) cells.
(B) The CD45RA2 population (gate R2) was further divided into quad-
rants based on CD127 and CD62L expression to define the following
populations: CD1271 CD62L2 TEM (UL), CD127
1 CD62L1 TCM
(UR), and CD1272 CD62L2 RA2 TEFF (LL). (C) The CD8
1CD45RA1
population (gate R3) was divided in a similar fashion to define the
CD1271CD62L1 TN (UR) and CD127
2 CD62L2 RA1TEFF (LL) popu-
lations. The same healthy control and chronic GVHD patients, who
were off IST, were used for illustration in each panel. Percentages dis-
played represent percent of CD8bright CD45RA2 (R2) or percent of
CD8bright CD45RA1 (R3).
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cally significant, whereas P values between ..01 and
#.05 were considered marginally significant.RESULTS
T Cell Counts in cGVHD and Tolerant Patients
The absolute number of CD31 and CD81 T cells
were comparable in cGVHD patients, tolerant pa-
tients, and normal controls, but the absolute number
of CD41T cells was significantly decreased in patients
with cGVHD (6606 35 cells/mL; P5 .009), especially
during IST (635 6 44 cells/mL, P 5 .006) compared
with controls (8566 47 cells/mL) (Table 1). The abso-
lute CD31 and CD41 T cell counts were greater with
increasing time post-HCT, and higher absoluteCD31, CD41, and CD81T cell counts were observed
in CMV-seropositive patients (P\ .001, P 5 .03, and
P\.001, respectively).We foundno statistically signif-
icant effect of patient or donor age, donor type, or use
of ISTon the numbers ofCD31 orCD81Tcells in pa-
tients with cGVHD or in tolerant patients (Table S1).
Expression of CD127
CD127, the IL-7 receptor, is essential for the sur-
vival of memory T cells, and its expression can be used
to defineT cell subsets with distinct functional proper-
ties [17]. We observed a significant decrease in the ex-
pression of CD127 on CD81 T cells from patients
with cGVHD compared with normal controls
(48% 6 3% versus 72% 6 3%, P\ .001) (Figure 3).
CD127 expression tended to normalize in tolerant pa-
tients compared with normal controls (62%6 4% ver-
sus 72%6 3%, P5 ns). In the multivariate regression
model, the percentage of CD81 T cells expressing
CD127 was lower in older patients (20.7%/year;
P\ .001) and patients who were CMV seropositive be-
foreHCT (213.5%, P5 .01) (Table S2A), but was not
associated with donor age (data not shown).
Analysis of CD81 T Cell Subsets
The percentage of CD81 TEFF cells was signifi-
cantly increased in patients with cGVHD overall com-
pared with normal controls (39%6 3% versus 19%6
3%, P\ .001) (Table 2A). There was also a 3-fold in-
crease in the absolute number of TEFF in cGVHD pa-
tients overall compared with normal controls (158 6
32 versus 54 6 14 cells/mL); however, this difference
was only of marginal significance when adjusted for
age (P5 .05) (Table 2B). IST had no significant effect
on either the percentage (38% 6 4% during IST ver-
sus 40%6 4% without IST, P5 ns) (Table 2A) or the
absolute number of TEFF inGVHDpatients (1446 50
cells/mL during IST versus 171 6 41 cells/mL without
IST, P 5 ns) (Table 2B). The observed increase in
TEFF in patients with cGVHD was balanced by a sig-
nificant decrease in the percentage and absolute num-
ber of TN compared with controls (20% 6 2% versus
35%6 4%, P5 .001; and 346 5 cells/mL versus 846
25 cells/mL, P 5 .003, respectively). Although there
was a significant decrease in the percentage of TEM
in cGVHD patients overall compared with controls
(13% 6 1% versus 19% 6 2%, P 5 .004), there was
no significant difference in the absolute number of
TEM in cGVHD patients overall compared with con-
trols (43 6 9 cells/mL versus 46 6 11 cells/mL, P 5
ns). There was also no significant difference in the per-
centage or absolute number of TCM cells in cGVHD
patients compared with controls (Table 2A-B).
In tolerant patients, neither the percentage nor the
absolute number of TEFF were significantly different
from normal controls (27% 6 4% versus 19% 6 3%,
Table 1. CD3+, CD4+, and CD8+ T cells in Chronic GVHD and Tolerant Patients*
CD3+ T Cells
Chronic GVHD
Tolerant (n 5 44) Normal Controls (n 5 33)Without IST (n 5 51)‡ During IST (n 5 118) Overall (n 5 169)
abs CD3† 1265 ± 85 1150 ± 77 1185 ± 60 1393 ± 110 1346 ± 69
abs CD4 716 ± 56 635 ± 44 660 ± 35 836 ± 76 856 ± 47
(0.006) (0.009)
abs CD8 468 ± 47 450 ± 40 455 ± 31 441 ± 42 410 ± 36
%CD4 58 ± 2 58 ± 2 58 ± 1 60 ± 2 64 ± 2
(0.05) (0.03) (0.03)
%CD8 35 ± 2 36 ± 1 36 ± 1 31 ± 2 30 ± 2
(0.02) (0.002)
CD4:CD8 ratio 2.3 ± 0.3 2.2 ± 0.1 2.2 ± 0.1 2.5 ± 0.3 2.6 ± 0.3
GVHD indicates graft-versus-host disease; IST, immunosuppressive therapy.
*Data consist of mean6 SEM and P values. All P values represent comparisons between patients and normal controls and are adjusted for age of patients
and normal controls. Adjusted P values >.05 are omitted.
†‘‘abs’’ indicates absolute number of cells/mL, and ‘‘%’’ indicates percentage of total CD3+ T cells.
‡The chronic GVHDwithout IST group includes 41 patients with ‘‘mild’’ and 10 patients with ‘‘moderate/severe’’ disease. No significant differences were
detected in the percentages of absolute numbers of CD3, CD4, or CD8 between these two subgroups (data not shown).
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P5 ns, respectively). There was also no significant dif-
ference in the absolute number of TN in tolerant pa-
tient compared with controls (63 6 16 versus 84 6
25 cells/mL, P5 ns), but there was a trend of marginal
significance for a decrease in the percentage of TN in
tolerant patients compared with controls (25 6 4%
versus 35% 6 4%, P 5 .05). There was no significant
difference in the percentage and absolute number of
TCM and TEM in tolerant patients compared with nor-
mal controls (Table 2A-B and Figure 4A-B).
Taken together, the changes in the percentage and
absolute numbers of TEFF and TN demonstrate
a marked increase of TEFF in cGVHD patients cou-
pled with a decline in both the percentage and absolute
number of TN, and a decline in the relative percentage
of TEM, whereas no significant changes were seen in
the percentage or absolute number of TCM cells.
These results overall suggest an expansion of TEFF
cells by proliferation and/or increased survival, andFigure 3. Comparison of CD127 expression on CD81 T cells in pa-
tients with chronic GVHD, tolerant patients, and normal controls.
The data are expressed as %CD1271/CD81 T cells. Samples include
24 patients with chronic GVHD off IST (19 mild and 5 moderate/severe
disease), 20 patients with chronic GVHD on IST, 21 tolerant patients,
and 20 normal healthy controls. All P values represent comparisons be-
tween patients and normal controls and are adjusted for age of patients
and normal controls.a decrease in the production or an increase in the re-
cruitment and activation of TN in cGVHD patients,
changes that tended to normalize in tolerant patients.
Additional changes were seen in the TEFF subsets
in cGVHD patients, especially during IST. The per-
centage and absolute number of RA2 TEFF cells were
increased in cGVHD patients overall compared with
normal controls (15% 6 2% versus 7% 6 1%, P 5
.006; and 67 6 15 versus 18 6 5 cells/mL, P 5 .05).
This increase was especially prominent in cGVHDpa-
tients without IST (20%6 2%, P\ .001; and 886 23
cells/mL, P 5 .01). The percentage of RA2 TEFF cells
was lower in cGVHD patients during IST (10%6 2%
during IST versus 20%6 2% without IST, P5 .009),
and there was a lower absolute number of RA2 TEFF
cells (43 6 17 cells/mL during IST versus 88 6 23
cells/mL without IST), but this apparent difference
was not statistically significant. The percentage and
absolute number of RA2 TEFF cells in patients during
IST were not significantly different from controls
(Table 2A-B and Figure 4A-B). The percentage of
RA1 TEFF was increased in cGVHD patients overall
compared with controls (24% 6 2% versus 12% 6
2%, P 5 .002) together with a trend for an increase
in the absolute number of RA1 TEFF cells (92 6 19
versus 37 6 10 cells/mL, P 5 .07). These increases in
percentage and absolute number of RA1 TEFF were
more prominent in cGVHD patients during IST
(28% 6 3%, P\ .001 and 101 6 33 cells/mL, P 5
.06) than in cGVHD patients without IST (21% 6
3%, P 5 .05 and 83 6 20 cells/mL, P 5 .16), whereas
the opposite was observed in RA2 TEFF cells indicat-
ing that the latter are IST sensitive. In tolerant pa-
tients, the percentage of RA2 TEFF remained
marginally increased compared with normal controls
(13% 6 2% versus 7% 6 1%, P 5 .05), whereas the
percentage of RA1 TEFF was essentially the same as
in normal controls (13% 6 2% versus 12% 6 2%,
P 5 ns). There was no significant difference in the
absolute number of RA1 or RA2TEFF cells in tolerant
Table 2A. Percentage of CD8+ T Cell Subsets in Chronic GVHD and Tolerant Patients*
Percentage of CD8+ T Cells
Chronic GVHD Patients
Tolerant Patients (n 5 21) Normal Controls (n 5 20)Without IST (n 5 24)† During IST (n 5 20) Overall (n 5 44)
TN 18 ± 3 23 ± 4 20 ± 2 25 ± 4 35 ± 4
(<0.001) (0.03) (0.001) (0.05)
TCM 8 ± 1 5 ± 1 6 ± 1 11 ± 2 8 ± 1
TEM 15 ± 2 10 ± 1 13 ± 1 20 ± 2 19 ± 2
(0.05) (0.001) (0.004)
TEFF overall 40 ± 4 38 ± 4 39 ± 3 27 ± 4 19 ± 3
(<0.001) (0.003) (<0.001) (0.29)
RA2 TEFF 20 ± 2 10 ± 2 15 ± 2 13 ± 2 7 ± 1
(<0.001) (0.006) (0.05)
RA+ TEFF 21 ± 3 28 ± 3 24 ± 2 13 ± 2 12 ± 2
(0.05) (<0.001) (0.002)
Other‡ 19 ± 1 24 ± 2 21 ± 1 17 ± 1 18 ± 2
GVHD indicates graft-versus-host disease; IST, immunosuppression therapy.
*Data consist of percentage of CD8+ T cells, and values are expressed as mean6 SEM (P values). All P values represent comparisons between patients
and normal controls and are adjusted for age of patients and normal controls. Adjusted P values >.05 are omitted.
†The chronic GVHD without IST group consists of 19 patients with ‘‘mild’’ and 5 patients with ‘‘moderate/severe’’ disease. Both subgroups showed sim-
ilar trends in CD8+ T cell subsets, including an increase in the percentage of TEFF in both ‘‘mild’’ and ‘‘moderate/severe’’ chronic GVHD patients (41%6
5% and 40% 6 8%), and a decrease in TN in both mild and moderate/severe GVHD patients (16% 6 3% and 22% 6 7%).
‡The ‘‘other’’ category includes 3 additional CD8+ T cell subsets (CD45RA2CD1272CD62L+, CD45RA+CD1272CD62L+, and CD45RA+
CD127+CD62L2).
1126 Biol Blood Marrow Transplant 17:1121-1132, 2011B. M. Grogan et al.patients (24.56 5 and 296 8 cells/mL) compared with
controls (37 6 10 and 18 6 5 cells/mL) (Table 2B and
Figure 4B).
In amultivariate regressionmodel, the percentages
of TN and overall TEFF (both RA
2 TEFF and RA
1
TEFF), but not TCM or TEM, were associated with pa-
tient age. The percentage of TN was lower in older in-
dividuals (20.7%/year, P \ .001), whereas the
percentage of RA2 and RA1 TEFF was higher in older
individuals (10.2%/y, P 5 .02; and 10.4%/year, P\
.001, respectively). The percentage of TN was lower
in CMV seropositive patients (28.1%, P 5 .03),
whereas the percentage of RA2 and RA1 TEFF was
higher in CMV seropositive patients (17.2%, P 5
.01; and 17.1%, P 5 .04, respectively). The percent-Table 2B. Absolute Number of CD8+ T Cell Subsets in Chronic GV
Absolute # CD8+ T Cells
Chronic GVHD Patients
Without IST (n 5 22)† During IST (n 5 20) O
TN 37 ± 8 30 ± 5
(0.01) (0.005)
TCM 23 ± 5 14 ± 6
TEM 48 ± 12 39 ± 13
TEFF overall 171 ± 41 144 ± 50
(0.04)
RA2TEFF 88 ± 23 43 ± 17
(0.01)
RA+ TEFF 83 ± 20 101 ± 33
(0.06)
Other‡ 57 ± 8 61 ± 18
GVHD indicates graft-versus-host disease; IST, immunosuppression therapy.
*Data consist of absolute cell counts (cells/mL) expressed as themean6 SEM (P
controls and are adjusted for age of patients and normal controls. Adjusted P
†The chronic GVHD without IST group consists of 18 patients with ‘‘mild’’ and
ilar trends in CD8+ T cell subsets, including an increase in the absolute number
175 6 71 cells/mL), and a decrease in TN in both mild and moderate/severe G
‡The ‘‘other’’ category includes 3 additional CD8+ T cell subsets (CD
CD127+CD62L2).age of TCM, but not TEM, was lower in CMV seropos-
itive patients (25.0%/year, P 5 .007) (Table S2A and
Figure 5). The multivariate analysis also confirmed
a decrease in absolute TN counts associated with age
(20.14 cells/mL/year, P 5 .005), and an increase in
TEFF cells associated with age (10.40 cells/mL/year,
P 5 .04) (Table S2B). Additionally, the multivariate
analysis showed an increase in the percentage TEFF
and absolute TEFF cell counts (P 5 .005 and P 5
.001, respectively) and revealed an increase in the abso-
lute TEM cell counts in CMV seropositive patients
(P 5 .004). The association between use of IST and
a lower percentage of RA2 TEFF in cGVHD patients
also remained significant in the multivariate regression
analysis (P 5 .009) (Table S2A).HD and Tolerant Patients*
Tolerant Patients (n 5 19) Normal Controls (n 5 12)verall (n 5 42)
34 ± 5 63 ± 16 84 ± 25
(0.003)
19 ± 4 20 ± 3 21 ± 6
43 ± 9 38 ± 6 46 ± 11
158 ± 32 54 ± 12 54 ± 14
(0.05)
67 ± 15 29 ± 8 18 ± 5
(0.05)
92 ± 19 24.5 ± 5 37 ± 10
(0.07)
59 ± 10 34 ± 5 40 ± 7
values). All P values represent comparisons between patients and normal
values >.05 are omitted.
4 patients with ‘‘moderate/severe’’ disease. Both subgroups showed sim-
of TEFF in both mild and moderate/severe GVHD patients (1706 48 and
VHD patients (36 6 9 and 40 6 16 cells/mL).
45RA2CD1272CD62L+, CD45RA+CD1272CD62L+, and CD45RA+
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Figure 4. Comparison na€ıve (TN), effector memory (TEM), RA
2 effec-
tor (RA2TEFF), and RA
1 effector (RA1TEFF) CD8
1 T cells in patients
with chronic GVHD, tolerant patients, and normal controls. (A) The
data are expressed as percentage of CD81 T cells. Samples include 24
patients with chronic GVHDoff IST (19 mild and 5 moderate/severe dis-
ease), 20 patients with chronic GVHD on IST, 21 tolerant patients, and
20 normal healthy controls. (B) The data are expressed as cells per mi-
croliter (cells/mL). Samples include 22 patients with chronic GVHD off
IST (18 mild and 4 moderate/severe disease), 20 patients with chronic
GVHD on IST, 19 tolerant patients, and 12 normal healthy controls.
All P values represent comparisons between patients and normal con-
trols and are adjusted for age of patients and normal controls.
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The percentage of HLA-DR1 cells in the CD81
population was not increased in patients with cGVHD
but was increased in tolerant patients compared with
controls (9% 6 3% versus 4% 6 1%, P 5 .002)
(Table 3). The percentage of HLA-DR1 cells was
lower in older patients (20.22%/year, P5 .01), but in-
creased with time fromHCT (11.29%/year, P\ .001)
(Table S3). The percentage of CD81 cells expressing
CD95 (Fas) was significantly increased in patients
with cGVHD during IST compared with controls
(59% 6 3% versus 40% 6 3%; P 5 .005), and in pa-
tients during IST compared with those without IST
(59% 6 3% versus 47% 6 4%, P 5 .008) (Tables 3
and S3). The percentage of CD951 cells was also
found to increase with age (10.5%/year, P 5
.005) (Table S3). CD95 expression was variable among
the CD81 T subsets. In normal controls, CD95 ex-
pression was lowest in TN cells (20% 6 2%), highest
in TCM (75%6 3%), and was higher in RA
2 comparedwith RA1 TEFF cells (64% 6 4% versus 32% 6 5%,
P\ .001). Similar parallel differences in CD95 expres-
sion were observed among TN, TCM, and RA
1 and
RA2 TEFF cells in cGVHD and tolerant patients
(data not shown). We found no statistically significant
difference in the expression of PD-1, a member of the
CD28/CTLA-4 family of T cell regulators, in tolerant
patients, or cGVHD patients either during or without
IST compared with normal controls. A history of
aGVHD, however, was associated with a lower per-
centage of cells expressing PD-1 (218.3%, P 5 .008)
(Table S3). AmongCD81T cell subsets, PD-1 expres-
sion in patients was lowest in TEM cells and highest in
RA2 TEFF cells (28% 6 4% and 45% 6 4%), both
similar to normal controls (TEM cells, 37% 6 6%;
and RA2 TEFF cells, 52% 6 5%).
Perforin and Granzyme A Expression
We observed a significant increased percentage of
CD81 cells expressing perforin in cGVHD patients
overall (46% 6 4%), but not in tolerant patients
(29% 6 5%), compared with controls (21% 6 5%)
(P5 .003 and P5 ns, respectively) (Table 3). Perforin
levels were also higher in CMV seropositive patients
(124.2%, P \ .001). In contrast, the percentage of
CD81 cells expressing granzyme A was increased in
tolerant patients compared with controls (27% 6 5%
versus 11% 6 4%, P 5 .004), but not in patients
with cGVHD (16% 6 3%, P 5 ns). Patient age,
time from HCT, and CMV serostatus had no signifi-
cant effect on granzyme expression (Table S3).
Proliferation and Apoptosis
The percentage of CD81 T cells expressing Ki-67,
a marker for recent proliferation, was increased in pa-
tients with cGVHD compared with controls (5% 6
1% versus 3% 6 0.5%, P 5 .04), especially in patients
who had cGVHD without IST (6% 6 2%, P 5 .01)
(Table 3). Similarly, we found a statistically significant
increase in the percentage of apoptotic CD81 T cells
in patients with cGVHD compared with normal con-
trols (50% 6 5% versus 31% 6 4%, P 5 .01) (Table
3). The percentages of Ki-671 and apoptotic cells in
the CD81 T population of tolerant patients were not
significantly different from controls. In cGVHD pa-
tients,Ki-67 expressionwas shown tobe significantly in-
creased in CD81 TCM cells during and without IST
(P 5 .01 and P 5 .007, respectively), and in TEM cells
in cGVHDpatientswithout ISTcomparedwith normal
controls (Figure6).Therewas also an increasedpercent-
age of Ki-671 cells in TN cells in cGVHD patients dur-
ing IST (2.5% 6 0.5%, P 5 .008), and in tolerant
patients (2.0%6 0.4%, P5 .03) comparedwith normal
controls (0.4%6 0.1%).ThehighestKi-671 expression
levels were seen among TEFF cells, especially among
RA2 TEFF cells in cGVHD patients without IST.
Figure 5. Comparison of the percentage (A) and absolute number (B) of na€ıve (TN) and effector (TEFF) CD81 T cells in patients and normal controls
according to age. For chronic GVHD patients, open circles represent patients without ISTand closed circles represent patients during IST (left panels).
Tolerant patients are represented by open triangles (middle panels), and normal controls are represented by open squares (right panels). R2 value rep-
resents the square of the correlation coefficient, and the P value is calculated from the R value using GraphPad Software.
1128 Biol Blood Marrow Transplant 17:1121-1132, 2011B. M. Grogan et al.During IST, Ki-67 expression was significantly sup-
pressed in RA1 TEFF cells (6% 6 1% versus 2% 6
0.3%, P 5 .02 and in the RA2 TEFF cells (15% 6 4%
versus 5%6 1%,P5 .05). These IST-associated effects
are consistent with the hypothesis that activation, prolif-
eration, and/or survival of TEFF cells in cGVHD
patients is inhibited by the administration of IST.DISCUSSION
This study population represents a large cross-
sectional cohort of patients from 1 year to 23 years
(median: 28 months) after HCT who were seen for
evaluation and management in our Long-term
Follow-Up Clinic. All patients received a systematic
Table 3. Percentage of CD8+ T Cell Activation Markers and Effector Molecules in Chronic GVHD and Tolerant Patients*
CD8+ T Cells
Chronic GVHD Patients
Tolerant Patients (n 5 20) Normal Controls (n 5 18)Without IST (n 5 17)† During IST (n 5 18) Overall (n 5 35)
%CD95 ‡ 47 ± 4 59 ± 3§ 53 ± 3 44 ± 3 40 ± 3
(0.005) (0.05)
%HLA-DR 2 ± 1 3 ± 1 3 ± 0.5 9 ± 3 4 ± 1
(0.002)
%PD-1 45 ± 6 50 ± 6 48 ± 4 48 ± 5 44 ± 4
%perforin§ 41 ± 5 51 ± 7 46 ± 4 29 ± 5 21 ± 5
(0.04) (0.001) (0.003)
%granzyme ¶ 15 ± 4 16 ± 4 16 ± 3 27 ± 5 11 ± 4
(0.004)
%Ki-67 6±2 4 ± 0.4 5 ± 1 3 ± 0.4 3 ± 0.5
(0.01) (0.04)
%annexint 50 ± 8 50 ± 7 50 ± 5 43 ± 4 31 ± 4
(0.01)
GVHD indicates graft-versus-host disease; IST, immunosuppression therapy.
*Data consist of mean6 SEM and P values. All P values represent comparisons between patients and normal controls and are adjusted for age of patients
and normal controls. Adjusted P values >.05 are omitted.
†The chronic GVHD without IST patient group consisted of 12 patients with ‘‘mild’’ and 5 patients with ‘‘moderate/severe’’ disease. There was a non-
significant trend for higher perforin expression in patients with ‘‘moderate/severe’’ compared with ‘‘mild’’ disease (52%6 6% versus 37%6 7%, P5.12),
but the expression of Ki-67 was similar in patients with ‘‘mild’’ and ‘‘moderate/severe’’ disease (6% 6 2% and 7% 6 3%).
‡CD95 expression was significantly greater in chronic GVHD patients during IST compared with chronic GVHD patients without IST (59%6 3% versus
47% 6 4%, P 5 .02).
§Perforin expression in patients was highest in the TEFF subset in both the RA
2 and RA+ TEFF subsets of patients (50%6 3% and 58%6 3%), and normal
controls (38% 6 6% and 51% 6 7%, respectively).
¶The highest levels of granzyme expression in tolerant patients was observed in TEM cells (43%6 7%), and in RA
2 and RA+ TEFF cells (37%6 6% and
41%6 6%). Among normal controls, granzyme expression in CD8 subsets was also higher in the RA2TEFF, RA
+ TEFF, and TEM cells (28%6 7%, 30%6 8%,
and 24% 6 7%) compared with the average for all CD8+ T cells (11% 6 4%).
tThe study population for the annexin staining included 27 patients (9 with chronic GVHD without IST; 7 with chronic GVHD during IST; and 11 tol-
erant patients), and 12 normal controls.
Biol Blood Marrow Transplant 17:1121-1132, 2011 1129CD81 Effector T Cells in Chronic GVHD and Toleranceand standard assessment for the presence of cGVHD
according to the guidelines of the recent NIHConsen-
sus Conference [11]. The patient category ‘‘cGVHD
without IST’’ included patients with both mild and
moderate/severe disease; however, similar trends in
CD8 subsets, activation markers, and effector pheno-
type were observed in both groups. Patients with noFigure 6. Comparison of percentage of Ki-67 expression in CD81
na€ıve (TN), central memory (TCM), effector memory (TEM), RA
2 effec-
tor (RA2TEFF), and RA
1 effector (RA1TEFF) T cells in patients with
chronic GVHD, tolerant patients, and normal controls. Samples include
15 patients with chronic GVHD off IST, 14 patients with chronic GVHD
on IST, 20 tolerant patients, and 16 normal healthy controls. P values
represent comparison of patients with normal controls and were calcu-
lated using a two-tailed t test. All P values represent comparisons be-
tween patients and normal controls and are adjusted for age of
patients and normal controls.clinical manifestations of cGVHD while still on IST
were excluded from the study.
The major finding in this study was an increase in
the percentage and absolute number of CD81 TEFF
cells. The increased expression of perforin, Ki-67,
and annexin that we observed in patients with cGVHD
compared with healthy controls suggests that mature
effector T cells are not only expanded in these patients,
but that they are also maintained in a state of activation
that persists for several months or years after trans-
plantation. Ki-67 expression levels were increased
not only in TEFF, but also in TCM and TEM, indicating
that there is increased proliferation among these ma-
ture CD81 T cells, a finding that may reflect compen-
sation for the increased recruitment of cells responsive
to host alloantigen and subsequent activation-induced
cell death. Despite the increased expression of Ki-67 in
TCM and TEM, there was no increase in the absolute
number of TCM and TEM in cGVHD patients com-
pared with normal controls, suggesting that the levels
of TCM and TEM in cGVHD patients, but not the
number of TEFF cells, remain under homeostatic con-
trol. Two of the markers for T cell activation used in
this study, HLA-DR and granzyme, gave unexpected
results in tolerant patients. Neither was significantly
increased in cGVHD patients, but their expression
was increased in tolerant patients, suggesting that the
resolution of GVHD can occur without complete nor-
malization of CD81 T cell phenotype as defined by
1130 Biol Blood Marrow Transplant 17:1121-1132, 2011B. M. Grogan et al.homeostasis in normal healthy controls. The func-
tional significance of this observation is unknown,
but it is consistent with the hypothesis that clinical tol-
erance in HCT recipients is induced and maintained
by an active cellular mechanism.
In contrast to the expansion of CD81TEFF cells in
cGVHD patients, there was a reciprocal decrease in
the percentages and absolute number of TN, and an in-
creased expression of Ki-67 by TN in cGVHDpatients
overall, consistent with the hypothesis that ongoing al-
loantigenic stimulation is driving the activation, differ-
entiation, and/or apoptosis of TN and resulting in the
accumulation of TEFF cells. In a multivariate regres-
sion model, the percentages of CD81 TN and TEFF
was found to change significantly with age in both pa-
tients and normal controls, with decreasing percent-
ages of TN and increasing percentages of TEFF in
older individuals. However, the absolute number of
TN remained significantly lower in patients with
cGVHD even after adjusting for the age effect. This
may be because of limited thymic function after
HCT, increased activation induced cell death, a defi-
ciency of growth factors, or other changes in the lym-
phoid microenvironment that compromise the
production and survival of T cells. These changes
may be further compounded by cytolytic and inflam-
matory consequences of cGVHD.
The use of IST had no apparent effect on the total
CD31 and CD81 T cell counts in cGVHD patients,
whereas CD41 T cell counts were significantly de-
creased in cGVHD patients during IST, suggesting
that CD41 T cells are more sensitive to IST than
CD81T cells in these patients. ISTwas also associated
with a decrease in the percentage and absolute number
of RA2TEFF and an increase in the percentage and ab-
solute number ofRA1TEFF, suggesting thatRA
2TEFF
are relatively sensitive to IST, whereas RA1 TEFF are
relatively resistant. This effect may be explained partly
by a decrease in apoptosis and Fas expression in the
RA1TEFF subset, comparedwith theRA
2TEFF subset
and the overall CD81 T cell population (data not
shown). The trend toward normalization of the per-
centage of TN in tolerant patients is consistent with
the clinical observation that immune reconstitution af-
ter HCT is delayed in the presence of cGVHD.
CMV serostatus of the patient had a significant ef-
fect on CD8 T cell subsets in this cohort of HCT pa-
tients, consistent with what is known about the
alterations in peripheral T cell homeostasis associated
with latent CMV infection [15]. CMV seropositive pa-
tients in our HCT cohort had higher CD31 and
CD81 T cell counts overall, but a lower percentage
of TN, and a higher percentage and absolute number
of CD81 TEFF cells, compared with seronegative pa-
tients. Peggs et al. studied T cell reconstitution during
the first 6 months following autologous HCT recipi-
ents and observed increased CD81T cell counts in pa-tients with active CMV infection compared with
patients who remained free of CMV infection [16].
The CMV effect on CD81 TN and TEFF in our study
paralleled the independent age effect. In a separate
study, we found no statistically significant association
of latent CMV infection with risk of cGVHD (Flowers
et al., unpublished results).
The first differentiationmarkers shown to be helpful
in defining T cell subsets were CD45RA and CCR7 in
a study by Sallusto et al. [18], where it was demonstrated
that ‘‘central memory’’ and ‘‘effector memory’’ CD81
T cells could be distinguished by the expression of
CD45RA2CCR71 and CD45RA2CCR72, respec-
tively.We chose an alternative approach to definingma-
ture central memory and effector cells based on studies
by Bachmann et al. [19] and Huster et al. [20]. Huster
et al. [20] demonstrated that CD127 is a marker for
memory CD81 T cells in the mouse, and they showed
that CD127highCD81 T cells had a high level of prolif-
eration andwerecapableof long-termsurvival compared
with CD127low CD81 T cells. They also demonstrated
that CD62L and CD127 expression following antigenic
priming distinguish TCM (CD127
highCD62Lhigh) from
TEM (CD127
highCD62Llow) CD81 T cells. Bachmann
et al. examined changes in CD62L1CD1271 TCM,
CD62L2CD1271 TEM, and CD62L
2CD1272 TEFF
CD81 T cells after acute and chronic viral infection in
mice. They showed thatCD62L2CD1271TEMexpand
early after antigenic stimulation, and that additional
stimulation leads to down-regulation of CD127 expres-
sion and a higher proportion ofCD62L2CD1272TEFF,
whereas cessation of stimulation leads to reexpression
of CD62L and increase in the percentage of
CD62L1CD1271 TCM [19]. They also showed that
TEFF display high levels of lytic activity and cytokine
production after antigenic stimulation. TCM, however,
showed high levels of IL-2 secretion and proliferation
[19]. In HIV patients with advanced disease and in-
creased viral load, Pairidini et al. [21] demonstrated
that decreased CD127 expression by CD81CD62L2
cells corresponded to an activated phenotype with in-
creased production of interferon-gamma (IFN-g) and
expressionofKi-67.Thesefindingsparallel our observa-
tions of an overall decrease in CD127 expression and in-
crease in CD62L2CD1272 TEFF associated with
cGVHD, whereas normalization of CD127 expression
and percentage of TEFF correlates with disease resolu-
tion and the development of tolerance.
There has been little information available about
CD81 T cell subsets in cGVHD. Yamashita et al. [9]
measured CD81 TCM as CD45RA
2CCR71 and re-
ported a roughly 2-fold increase in the percentage of
CD81 TCM in cGVHD patients compared with nor-
mal controls (23.3% 6 2.0% versus 11.8% 6 1.0%,
P \ .0001). We defined TCM as explained above
(CD45RA2CD62L1CD1271) and observed no sig-
nificant difference in either the percentage or absolute
Biol Blood Marrow Transplant 17:1121-1132, 2011 1131CD81 Effector T Cells in Chronic GVHD and Tolerancenumber of TCM in cGVHD patients compared with
normal controls, with only a nonsignificant trend for
lower numbers of TCM during IST. D’Asaro et al.
[10] showed an increased in the percentage of
CD45RA1CCR72 cells, which they termed TEMRA
cells, and a decrease in percentage of CD81 TN cells
in a study of 12 patients with cGVHD, all of which
were on IST at the time of study. We also observed
an increase in a CD45RA1 TEFF subset in patients
with cGVHD overall, but this increase was only mar-
ginal in patients without IST compared with controls
(21% 6 3% versus 12% 6 2%, P 5 .05), whereas
the increase was muchmore significant in cGVHD pa-
tients during IST (28%6 3.0%, P\ .001), suggesting
that use of IST leads to an expansion rather than a re-
duction of this RA1TEFF subset. The RA
2TEFF pop-
ulation, however, is shown to be more significantly
increased in patients with GVHD without IST and,
in contrast to the RA1 TEFF population, is decreased
to normal levels in patients during IST. CD45RA1
TEFF have been described as cells approaching ‘‘end-
stage differentiation’’ by some investigators, including
Almanzar et al. [22] in a study of CMV immunity.
CD45RA1TEFF are not a uniform population but var-
iably express granzyme B, tumor necrosis factor-alpha
(TNF-a), IFN-g, and FasL [23]. Carrasco et al. [24]
studied clonal human effector T cell responses ex
vivo in a melanoma model and demonstrated that
CD45RA1CCR72MAGE-3 specific cytotoxic T cells
(CTL) could proliferate after rechallenge with anti-
gen. These cells subsequently lose expression of
CD45RA and temporarily express CCR7. Expression
of CD45RA recovered, and CCR7 expression was
lost again, at 10 to 15 days following antigen stimula-
tion. These investigators concluded that CD45RA
expression is not a marker of terminal differentiation
in memory CD81 T cells, but rather that
CD45RA1CCR72CD81 T cells are ‘‘transitional’’ or
‘‘stable resting’’ effector T cells. Assuming that
CD45RA expression by CD62L2CD1272CD81
T cells in cGVHD patients is analogous to the ex
vivo tumor model of Carrasco et al. [24], we would in-
fer that RA2 TEFF have recently encountered and re-
sponded to host alloantigen, whereas RA1 TEFF have
not. The concept that RA2 TEFF are activated while
RA1TEFF are quiescent is consistent with the observa-
tion that the percentage of RA2 TEFF is reduced in
cGVHD patients during IST indicating the effective-
ness of IST in blocking activation of CD81 TEFF,
whereas the relative number of quiescent RA1 TEFF
is increased in patients receiving IST.
Clonal deletion and T cell exhaustion have previ-
ously been implicated in the development of tolerance.
Programmed Death 1 (PD-1) is a cell-surface receptor
that has been shown to be involved in the negative reg-
ulation of CD81T cells and has been implicated in the
development of T cell anergy or nonresponsiveness inanimal models of chronic infection. Several recent
clinical studies have shown an up-regulation of PD-1
associated with T cell exhaustion of CD81 T cells in
patients chronically infected with HIV and HCV
[25-28]. We observed no significant difference in
PD-1 expression in patients with cGVHD or in toler-
ant patients compared with healthy controls, suggest-
ing that PD-1 probably does not mediate the
development of nonresponsiveness to host alloantigen
in HCT recipients. Evidence for clonal deletion by ac-
tivation induced cell death, however, is supported by
the evidence showing increased expression of Ki-67
and increased apoptosis in patients with cGVHDcom-
pared with tolerant patients and normal controls.
In summary, the results reported here support the
hypothesis that there is a sustained activation and ex-
pansion of CD81 T cells in patients with cGVHD.
The relevant findings include an overall decrease in
CD127 expression, an expansion in the percentage
and absolute number of CD81 TEFF cells, and an in-
crease in perforin, Ki-67, and annexin expression in pa-
tients with cGVHD. The increase in effector T cells
was most prominent in older patients and patients
who were CMV seropositive before transplantation.
The increase in TEFF cells was accompanied by a recip-
rocal decrease in TN, whereas the absolute number of
TCM and TEM remained within the normal range both
in cGVHD and tolerant patients. Perforin, Ki-67, and
annexin levels in CD81 T cells normalize in tolerant
patients, but HLA-DR and granzyme A expression
are increased in tolerant patients. PD-1 expression
was within the normal range in both cGVHD and tol-
erant patients. IST use was shown to result in a de-
crease in the relative and absolute number of CD81
T cells that were RA2 TEFF, and an increase in RA
1
TEFF cells. Overall, these results are consistent with
the hypothesis that CD81 T cells play a role in medi-
ating the immunopathology of cGVHD, and they fur-
thermore suggest that tolerance after HCT does not
necessarily correlate with a normalization of the
CD81 T cell phenotype. Although our study was lim-
ited to a cross-sectional analysis of cGVHD and toler-
ant patients, the evidence provided are sufficiently
compelling to prompt future longitudinal studies
that more thoroughly explore differences in signaling,
intracellular pathways, and effector functions of CD81
T cells in these patients.ACKNOWLEDGMENTS
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